Device Trial Radar · NCT00784043
Bilateral Cochlear Implantation in Children With the MED-EL Cochlear Implant
Last checked: Nov 20, 2026Latest source record: May 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
37
Actual
Start
Mar 2004
Primary completion
Sep 2009
Study completion Feb 2017
Sponsor
- Lead sponsor
- Med-El CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 3, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 months, up to 36 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate and document longitudinal efficacy in young children implanted bilaterally with MED-EL COMBI 40+ / PULSARCI100/SONATATI100 cochlear implant systems.
Conditions
- Hearing Loss
Interventions
Cochlear ImplantDevice
Bilateral Implantation in children
Primary outcomes
What the sponsor says the trial is designed to measure.
- Longitudinal Efficacy in Young Children Implanted Bilaterally With MED-EL COMBI 40+ / PULSARCI100/SONATATI100 Cochlear Implant SystemsTime frame: 60 months post initial stimulation
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Nemours Children's Clinic
Jacksonville, Florida
Children's Healthcare of Atlanta
Atlanta, Georgia
Cleveland Clinic Foundation
Cleveland, Ohio
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.